International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation

被引:2
作者
Charlton, Michael R. [1 ]
Gane, Edward J. [2 ]
Shukla, Aakash [3 ]
Dashtseren, Bekhbold [4 ,5 ]
Duger, Davaadorj [5 ]
Muljono, David H. [6 ,7 ,8 ,9 ]
Payawal, Diana A. [10 ]
Jargalsaikhan, Ganbolor [4 ,5 ]
Purnomo, Hery D. [11 ]
Cua, Ian H. [12 ]
Hasan, Irsan [13 ,14 ]
Sollano, Jose, Jr. [15 ]
Win, Khin Maung [16 ,17 ]
Lesmana, Laurentius A. [18 ]
Salih, Mohammad [19 ]
Pham Thi Thu Thuy [20 ]
Shankar, Ravi [21 ]
Saraswat, Vivek A. [22 ]
机构
[1] Univ Chicago, Transplant Inst, Ctr Liver Dis, Biol Sci, Chicago, IL 60637 USA
[2] Auckland City Hosp, New Zealand Liver Transplant Unit, Auckland, New Zealand
[3] LTMMC & LTMGH, Dept Gastroenterol, Sion Mumbai, India
[4] Liver Ctr Clin Res Ctr, Ulaanbaatar, Mongolia
[5] Mongolian Natl Univ Med Sci, Ulaanbaatar, Mongolia
[6] Eijkman Inst Mol Biol, Jakarta, Indonesia
[7] Univ Hasanuddin, Fac Med, Makassar, Indonesia
[8] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[9] Minist Hlth, Natl Expert Comm Hepatitis, South Jakarta, Indonesia
[10] Fatima Med Univ Ctr, Digest Hlth Ctr, Dept Internal Med, Manila, Philippines
[11] Diponegoro Univ, Dr Kariadi Hosp, Dept Internal Med, Div Gastroenterohepatol, Semarang, Indonesia
[12] St Lukes Med Ctr, Inst Digest & Liver Dis, Quezon City, Philippines
[13] Univ Indonesia, Fac Med, Dept Internal Med, Div Hepatol, Jakarta, Indonesia
[14] Dr Cipto Mangunkusumo Hosp, Jakarta, Indonesia
[15] Univ Santo Tomas, Fac Med & Surg, Manila, Philippines
[16] Univ Med 1, Dept Hepatol, Yangon, Myanmar
[17] Minist Hlth & Sports, Naypyitaw, Myanmar
[18] Univ Indonesia, Dr Cipto Mangunkusumo Teaching Hosp, Dept Med, Jakarta, Indonesia
[19] Quaid E Azam Int Hosp, Dept Hepatol, Islamabad, Pakistan
[20] Med Med Ctr, Hepatol Dept, Ho Chi Minh City, Vietnam
[21] Mylan Labs Ltd, Global Ctr Excellence Lead Infect Dis & Head Med, Canonsburg, PA USA
[22] SGPGIMS, Dept Gastroenterol, Lucknow, Uttar Pradesh, India
关键词
SOFOSBUVIR PLUS RIBAVIRIN; FIXED-DOSE COMBINATION; GENOTYPE; INFECTION; TREATMENT-EXPERIENCED PATIENTS; SUSTAINED VIROLOGICAL RESPONSE; PATIENT-REPORTED OUTCOMES; REAL-WORLD EFFECTIVENESS; TREATMENT-NAIVE PATIENTS; OPEN-LABEL; HCV INFECTION;
D O I
10.1097/TP.0000000000002453
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The population of Asia exceeds 4.4 billion people. Chronic hepatitis C virus (HCV) infection in Asia is characterized by specific distribution of genotypes, lack of access to specific therapeutic agents, relatively high cost of treatment, and lack of experienced healthcare providers. Clear consensus on the diagnosis, management, and monitoring of HCV infection specific to the Asian region is a major unmet need. The consensus guidelines documents that have been published to date by major medical societies presume access to an array of direct acting antiviral agents and diagnostic tests that are not broadly applicable to resource limited settings, including Asia. Methods. To address the lack of an Asia-specific set of HCV treatment guidelines, we assembled a panel of 15 HCV experts in the field of hepatology from India, Indonesia, Myanmar, Vietnam, Pakistan, Philippines, and Mongolia convened in April 2017 to review the updated literature and provide recommendations on the diagnosis and management of chronic HCV infection that reflects local conditions. Results. An evidence-based comprehensive compilation of the literature supported by the graded recommendations from the expert panel for the optimization of the diagnosis, pretreatment, on treatment, and posttreatment assessments, and management of chronic HCV infection has been presented in this article. Conclusions. With the evolving treatment landscape and addition of several new direct-acting antiviral agents and combination regimens into the therapeutic armamentarium, the current article may serve as a guide to the clinicians in optimizing the diagnosis and treatment selection for the management of chronic HCV infection in resource-limited settings.
引用
收藏
页码:733 / 746
页数:14
相关论文
共 105 条
[61]   Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+) [J].
Leroy, Vincent ;
Angus, Peter ;
Bronowicki, Jean-Pierre ;
Dore, Gregory J. ;
Hezode, Christophe ;
Pianko, Stephen ;
Pol, Stanislas ;
Stuart, Katherine ;
Tse, Edmund ;
McPhee, Fiona ;
Bhore, Rafia ;
Jimenez-Exposito, Maria Jesus ;
Thompson, Alexander J. .
HEPATOLOGY, 2016, 63 (05) :1430-1441
[62]   Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis [J].
Liao, Haotian ;
Tan, Ping ;
Zhu, Zexin ;
Yan, Xiaokai ;
Huang, Jiwei .
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2017, 41 (03) :262-271
[63]   A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-na⟨ve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus [J].
Lim, Young-Suk ;
Ahn, Sang Hoon ;
Lee, Kwan Sik ;
Paik, Seung Woon ;
Lee, Youn-Jae ;
Jeong, Sook-Hyang ;
Kim, Ju-Hyun ;
Yoon, Seung Kew ;
Yim, Hyung Joon ;
Tak, Won Young ;
Han, Sang-Young ;
Yang, Jenny C. ;
Mo, Hongmei ;
Garrison, Kimberly L. ;
Gao, Bing ;
Knox, Steven J. ;
Pang, Phillip S. ;
Kim, Yoon Jun ;
Byun, Kwan-Soo ;
Kim, Young Seok ;
Heo, Jeong ;
Han, Kwang-Hyub .
HEPATOLOGY INTERNATIONAL, 2016, 10 (06) :947-955
[64]   12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens [J].
Luetkemeyer, Anne F. ;
McDonald, Cheryl ;
Ramgopal, Moti ;
Noviello, Stephanie ;
Bhore, Rafia ;
Ackerman, Peter .
CLINICAL INFECTIOUS DISEASES, 2016, 62 (12) :1489-1496
[65]   Diagnostics for the developing world [J].
Mabey, D ;
Peeling, RW ;
Ustianowski, A ;
Perkins, MD .
NATURE REVIEWS MICROBIOLOGY, 2004, 2 (03) :231-240
[66]   Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial [J].
Manns, Michael ;
Samuel, Didier ;
Gane, Edward J. ;
Mutimer, David ;
McCaughan, Geoff ;
Buti, Maria ;
Prieto, Martin ;
Luis Calleja, Jose ;
Peck-Radosavljevic, Markus ;
Mullhaupt, Beat ;
Agarwal, Kosh ;
Angus, Peter ;
Yoshida, Eric M. ;
Colombo, Massimo ;
Rizzetto, Mario ;
Dvory-Sobol, Hadas ;
Denning, Jill ;
Arterburn, Sarah ;
Pang, Phillip S. ;
Brainard, Diana ;
McHutchison, John G. ;
Dufour, Jean-Francois ;
Van Vlierberghe, Hans ;
van Hoek, Bart ;
Forns, Xavier .
LANCET INFECTIOUS DISEASES, 2016, 16 (06) :685-697
[67]   A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care [J].
McGowan, Christopher E. ;
Monis, Ali ;
Bacon, Bruce R. ;
Mallolas, Josep ;
Goncales, Fernando L. ;
Goulis, Ioannis ;
Poordad, Fred ;
Afdhal, Nezam ;
Zeuzem, Stefan ;
Piratvisuth, Teerha ;
Marcellin, Patrick ;
Fried, Michael W. .
HEPATOLOGY, 2013, 57 (04) :1325-1332
[68]   Global Distribution and Prevalence of Hepatitis C Virus Genotypes [J].
Messina, Jane P. ;
Humphreys, Isla ;
Flaxman, Abraham ;
Brown, Anthony ;
Cooke, Graham S. ;
Pybus, Oliver G. ;
Barnes, Eleanor .
HEPATOLOGY, 2015, 61 (01) :77-87
[69]   Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial [J].
Mizokami, Masashi ;
Yokosuka, Osamu ;
Takehara, Tetsuo ;
Sakamoto, Naoya ;
Korenaga, Masaaki ;
Mochizuki, Hitoshi ;
Nakane, Kunio ;
Enomoto, Hirayuki ;
Ikeda, Fusao ;
Yanase, Mikio ;
Toyoda, Hidenori ;
Genda, Takuya ;
Umemura, Takeji ;
Yatsuhashi, Hiroshi ;
Ide, Tatsuya ;
Toda, Nobuo ;
Nirei, Kazushige ;
Ueno, Yoshiyuki ;
Nishigaki, Yoichi ;
Betular, Juan ;
Gao, Bing ;
Ishizaki, Akinobu ;
Omote, Masa ;
Mo, Hongmei ;
Garrison, Kim ;
Pang, Phillip S. ;
Knox, Steven J. ;
Symonds, William T. ;
McHutchison, John G. ;
Izumi, Namiki ;
Omata, Masao .
LANCET INFECTIOUS DISEASES, 2015, 15 (06) :645-653
[70]   Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study [J].
Molina, Jean-Michel ;
Orkin, Chloe ;
Iser, David M. ;
Zamora, Francisco-Xavier ;
Nelson, Mark ;
Stephan, Christoph ;
Massetto, Benedetta ;
Gaggar, Anuj ;
Ni, Liyun ;
Svarovskaia, Evguenia ;
Brainard, Diana ;
Subramanian, G. Mani ;
McHutchison, John G. ;
Puoti, Massimo ;
Rockstroh, Juergen K. .
LANCET, 2015, 385 (9973) :1098-1106